MX350234B - Compuestos de enlace especificos de bacterias gram-positivas. - Google Patents
Compuestos de enlace especificos de bacterias gram-positivas.Info
- Publication number
- MX350234B MX350234B MX2014012186A MX2014012186A MX350234B MX 350234 B MX350234 B MX 350234B MX 2014012186 A MX2014012186 A MX 2014012186A MX 2014012186 A MX2014012186 A MX 2014012186A MX 350234 B MX350234 B MX 350234B
- Authority
- MX
- Mexico
- Prior art keywords
- gram
- binding compounds
- positive bacteria
- specific binding
- bacteria specific
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1278—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Bacillus (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a un anticuerpo o parte funcional del mismo que se enlaza a un epítopo dependiente de repetición de serina-aspartato (SD) de una proteína de repetición de SD (sdr), en done el anticuerpo o parte funcional del mismo se acopla a un agente citotóxico para formar un conjugado de anticuerpo-fármaco.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22587809P | 2009-07-15 | 2009-07-15 | |
EP09165558 | 2009-07-15 | ||
PCT/NL2010/050456 WO2011008092A2 (en) | 2009-07-15 | 2010-07-15 | Gram-positive bacteria specific binding compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX350234B true MX350234B (es) | 2017-08-30 |
Family
ID=41467048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014012186A MX350234B (es) | 2009-07-15 | 2010-07-15 | Compuestos de enlace especificos de bacterias gram-positivas. |
Country Status (24)
Country | Link |
---|---|
US (9) | US20110020323A1 (es) |
EP (1) | EP2454284B1 (es) |
JP (3) | JP6192294B2 (es) |
KR (1) | KR101832201B1 (es) |
CN (2) | CN105440133A (es) |
AR (1) | AR077756A1 (es) |
AU (2) | AU2010271582B2 (es) |
BR (1) | BR112012000953A8 (es) |
CA (1) | CA2768204A1 (es) |
DK (1) | DK2454284T3 (es) |
EA (1) | EA031447B1 (es) |
ES (1) | ES2673323T3 (es) |
HK (1) | HK1222418A1 (es) |
HU (1) | HUE038277T2 (es) |
IL (3) | IL217497A (es) |
MX (1) | MX350234B (es) |
NZ (2) | NZ616921A (es) |
PL (1) | PL2454284T3 (es) |
SG (2) | SG10201704269RA (es) |
SI (1) | SI2454284T1 (es) |
TR (1) | TR201809128T4 (es) |
TW (2) | TWI502068B (es) |
WO (1) | WO2011008092A2 (es) |
ZA (2) | ZA201200363B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ600075A (en) | 2005-12-09 | 2013-12-20 | Amc Amsterdam | Means and methods for influencing the stability of antibody producing cells |
WO2007067032A1 (en) | 2005-12-09 | 2007-06-14 | Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
US8617554B2 (en) | 2009-05-13 | 2013-12-31 | Genzyme Corporation | Anti-human CD52 immunoglobulins |
CA2768207C (en) | 2009-07-15 | 2019-12-03 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
NZ616921A (en) | 2009-07-15 | 2015-06-26 | Genentech Inc | Gram-positive bacteria specific binding compounds |
PL2646466T3 (pl) * | 2010-12-02 | 2017-09-29 | Aimm Therapeutics B.V. | Środki i sposoby do wytwarzania przeciwciał o wysokim powinowactwie |
CN102559733A (zh) * | 2012-03-13 | 2012-07-11 | 黑龙江省科学院微生物研究所 | 导入clfA基因的乳酸乳球菌基因工程菌株的构建方法 |
UY34887A (es) * | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
WO2014074540A2 (en) | 2012-11-06 | 2014-05-15 | Medimmune, Llc | Antibodies to s. aureus surface determinants |
WO2014142117A1 (ja) | 2013-03-12 | 2014-09-18 | 全薬工業株式会社 | 抗ブドウ球菌抗体、その製造方法並びにその使用 |
AR095199A1 (es) * | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
KR20160015286A (ko) * | 2013-05-31 | 2016-02-12 | 제넨테크, 인크. | 항-세포벽 테이코산 항체 및 접합체 |
US9803002B2 (en) | 2013-05-31 | 2017-10-31 | Genentench, Inc. | Anti-wall teichoic antibodies and conjugates |
KR20160015227A (ko) * | 2013-05-31 | 2016-02-12 | 제넨테크, 인크. | 항-세포벽 테이코산 항체 및 접합체 |
RS64268B1 (sr) | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
EP3083678B1 (en) | 2013-12-17 | 2019-04-03 | Aimm Therapeutics B.V. | Means and methods for counteracting myeloproliferative or lymphoproliferative disorders |
DK3099709T3 (da) | 2014-01-31 | 2020-02-03 | Aimm Therapeutics Bv | Midler og fremgangsmåder til fremstilling af stabile antistoffer |
MX2017007231A (es) * | 2014-12-03 | 2017-11-08 | Genentech Inc | Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos. |
BR112017011325A2 (pt) * | 2014-12-03 | 2020-07-21 | Genentech, Inc. | ?composto de conjugado anticorpo?antibiótico, composição, método de tratamento de uma infecção, método para matar staph aureus, processo para produzir o conjugado, kit para o tratamento de uma infecção, intermediários antibiótico-ligante e ligante-droga? |
WO2016200926A1 (en) * | 2015-06-09 | 2016-12-15 | Techulon Inc. | Peptide nucleic acid molecules for treatment of gram positive bacterial infection |
US10407510B2 (en) | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
MX2019012076A (es) | 2017-05-30 | 2019-12-09 | Bristol Myers Squibb Co | Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1). |
EP4306542A3 (en) | 2017-05-30 | 2024-04-17 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
US11280788B2 (en) | 2019-01-31 | 2022-03-22 | Fresenius Medical Care Holdings, Inc. | Rapid diagnosis of peritonitis in peritoneal dialysis patients |
KR102301987B1 (ko) * | 2019-11-14 | 2021-09-13 | 연세대학교 산학협력단 | 항체 선별 방법, 박테리아 오염 진단 방법 및 박테리아 오염 진단 키트 |
WO2023129822A2 (en) * | 2021-12-28 | 2023-07-06 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically modified bacterial peptidoglycan compositions and uses thereof |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995034655A2 (en) | 1994-06-07 | 1995-12-21 | The Rockefeller University | Surface protein of staphylococcus aureus |
US6994855B1 (en) | 1994-08-22 | 2006-02-07 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
US6008341A (en) | 1994-08-22 | 1999-12-28 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
CA2208780C (en) * | 1995-01-30 | 2010-03-30 | Peter Truog | Antitumor and anticholesterol preparations comprising lipoteichoic acid lta-t of streptococcus sp dsm 8747 |
SE9602496D0 (sv) | 1996-06-20 | 1996-06-20 | Bengt Guss | Method and means for producing a fibrinogen binding protein and its use in biotechnology |
US6610293B1 (en) | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
US6680195B1 (en) | 1997-11-26 | 2004-01-20 | Inhibitex, Inc. | Extracellular matrix-binding proteins from staphylococcus aureus |
US6322788B1 (en) * | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
CA2341177A1 (en) | 1998-08-31 | 2000-03-09 | Inhibitex, Inc. | Staphylococcal immunotherapeutics via donor selection and donor stimulation |
US6692739B1 (en) * | 1998-08-31 | 2004-02-17 | Inhibitex, Inc. | Staphylococcal immunotherapeutics via donor selection and donor stimulation |
WO2000012689A1 (en) * | 1998-08-31 | 2000-03-09 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Polypeptides and polynucleotides from coagulase-negative staphylococci |
US6703025B1 (en) * | 1998-08-31 | 2004-03-09 | Inhibitex, Inc. | Multicomponent vaccines |
ATE422368T1 (de) | 1998-08-31 | 2009-02-15 | Inhibitex Inc | Multikomponenten impfstoffe gegen staphylococcus aureus |
US20030165527A1 (en) | 1998-12-22 | 2003-09-04 | Bengt Guss | Novel fibronectin-binding protein |
US20040038327A1 (en) | 1999-08-31 | 2004-02-26 | Foster Timothy J. | Antibodies to polypeptides from coagulase-negative staphylococci |
IL157041A0 (en) * | 2001-01-26 | 2004-02-08 | Inhibitex Inc | Monoclonal antibodies to the clfa protein and method of use in treating and preventing infections |
GB0127983D0 (en) * | 2001-11-22 | 2002-01-16 | Neutec Pharma Plc | Treatment of micro-organism infection |
US8420353B2 (en) | 2002-03-22 | 2013-04-16 | Aprogen, Inc. | Humanized antibody and process for preparing same |
JP4686188B2 (ja) | 2002-09-13 | 2011-05-18 | ザ テキサス エイ アンド エム ユニバースティ システム | グラム陽性菌由来の表面固定化タンパク質を同定するためのバイオインフォマティクス法及びそれによって得られるタンパク質 |
US20040151737A1 (en) | 2003-02-05 | 2004-08-05 | University Of Tennessee | Streptococcal serum opacity factors and fibronectin-binding proteins and peptides thereof for the treatment and detection of streptococcal infection |
NZ561879A (en) | 2003-03-07 | 2009-05-31 | Wyeth Corp | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
US20070026011A1 (en) | 2003-05-29 | 2007-02-01 | Inhibitex, Inc. | Sdr proteins from staphylococcus capitis and their use in preventing and treating infections |
PL1791565T3 (pl) * | 2004-09-23 | 2016-10-31 | Modyfikowane cysteiną przeciwciała i koniugaty | |
WO2006076058A1 (en) * | 2005-01-10 | 2006-07-20 | Nabi Biopharmaceuticals | Method of treating staphylococcus aureus infection |
US8475798B2 (en) | 2005-06-16 | 2013-07-02 | Inhibitex, Inc. | Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein |
EP1996231A4 (en) | 2006-02-22 | 2010-09-15 | Texas A & M Univ Sys | ANTIBODIES RECOGNIZING A HIGHLY EXPRESS PUTATIVE ANTIGEN OF SARM-C AND METHODS OF USE |
HUE027099T2 (hu) * | 2006-06-06 | 2016-08-29 | Crucell Holland Bv | Humán kötõmolekulák staphylococcus elleni ölõaktivitással és alkalmazásuk |
US20110130544A1 (en) * | 2007-03-30 | 2011-06-02 | Medimmune, Llc | Antibodies with decreased deamidation profiles |
CA2683568A1 (en) | 2007-05-08 | 2008-11-20 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
CN101302504B (zh) * | 2007-05-11 | 2011-12-21 | 上海高科联合生物技术研发有限公司 | 一种抗体亲和层析纯化溶葡萄球菌酶的方法 |
PT2176296E (pt) | 2007-07-16 | 2012-05-14 | Genentech Inc | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização |
JP2010533495A (ja) | 2007-07-16 | 2010-10-28 | ジェネンテック, インコーポレイテッド | ヒト化CD79b抗体およびイムノコンジュゲートならびにそれらの使用 |
US20090162379A1 (en) * | 2007-10-01 | 2009-06-25 | Magnus Hook | Inhibitors of S. aureus SdrD protein attachment to cells and uses therefor |
BRPI0818780A2 (pt) | 2007-10-19 | 2015-04-22 | Genentech Inc | Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos |
BRPI0906997A2 (pt) | 2008-01-31 | 2015-07-07 | Trinity College Dublin | Proteína, uso da proteína combinante ou fragmento da mesma, método para induzir uma resposta imune em um individuo, método para tratar um paceinte, construção de ácido nicleico, vetor de ezpressão o ucélula hospedeira, vacina, anticorpo, e, composição farmaceutica |
MY157403A (en) | 2008-01-31 | 2016-06-15 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
WO2010005513A2 (en) | 2008-06-30 | 2010-01-14 | The Texas A&M University System | Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof |
SI2445522T1 (sl) | 2009-06-22 | 2017-10-30 | Wyeth Llc | Imunogeni sestavki antigenov Staphylococcusa aureusa |
NZ616921A (en) | 2009-07-15 | 2015-06-26 | Genentech Inc | Gram-positive bacteria specific binding compounds |
US9353160B2 (en) | 2009-07-16 | 2016-05-31 | Glaxosmithkline Biologicals S.A. | Method of prophlactically treating infection using a recombinant fibrinogen binding protein clumping factor A (ClfA) or fragment thereof |
-
2010
- 2010-07-15 NZ NZ616921A patent/NZ616921A/en not_active IP Right Cessation
- 2010-07-15 EA EA201390967A patent/EA031447B1/ru not_active IP Right Cessation
- 2010-07-15 SI SI201031701T patent/SI2454284T1/en unknown
- 2010-07-15 TW TW099123405A patent/TWI502068B/zh not_active IP Right Cessation
- 2010-07-15 CA CA2768204A patent/CA2768204A1/en not_active Abandoned
- 2010-07-15 MX MX2014012186A patent/MX350234B/es unknown
- 2010-07-15 CN CN201510639968.3A patent/CN105440133A/zh active Pending
- 2010-07-15 TR TR2018/09128T patent/TR201809128T4/tr unknown
- 2010-07-15 KR KR1020127003839A patent/KR101832201B1/ko active IP Right Grant
- 2010-07-15 NZ NZ598063A patent/NZ598063A/en not_active IP Right Cessation
- 2010-07-15 WO PCT/NL2010/050456 patent/WO2011008092A2/en active Application Filing
- 2010-07-15 DK DK10734844.3T patent/DK2454284T3/en active
- 2010-07-15 SG SG10201704269RA patent/SG10201704269RA/en unknown
- 2010-07-15 JP JP2012520555A patent/JP6192294B2/ja not_active Expired - Fee Related
- 2010-07-15 AU AU2010271582A patent/AU2010271582B2/en not_active Ceased
- 2010-07-15 US US12/837,358 patent/US20110020323A1/en not_active Abandoned
- 2010-07-15 EP EP10734844.3A patent/EP2454284B1/en not_active Not-in-force
- 2010-07-15 HU HUE10734844A patent/HUE038277T2/hu unknown
- 2010-07-15 BR BR112012000953A patent/BR112012000953A8/pt not_active Application Discontinuation
- 2010-07-15 AR ARP100102587A patent/AR077756A1/es unknown
- 2010-07-15 SG SG2012002622A patent/SG177653A1/en unknown
- 2010-07-15 CN CN201080041138.6A patent/CN102666583B/zh not_active Expired - Fee Related
- 2010-07-15 TW TW104126578A patent/TW201610153A/zh unknown
- 2010-07-15 PL PL10734844T patent/PL2454284T3/pl unknown
- 2010-07-15 ES ES10734844.3T patent/ES2673323T3/es active Active
-
2011
- 2011-11-28 US US13/305,659 patent/US8617556B2/en not_active Expired - Fee Related
-
2012
- 2012-01-12 IL IL217497A patent/IL217497A/en not_active IP Right Cessation
- 2012-01-17 ZA ZA2012/00363A patent/ZA201200363B/en unknown
-
2013
- 2013-03-05 US US13/786,206 patent/US9399673B2/en active Active
- 2013-03-05 US US13/786,215 patent/US9090677B2/en not_active Expired - Fee Related
- 2013-12-11 US US14/103,715 patent/US9266943B2/en not_active Expired - Fee Related
-
2014
- 2014-01-27 ZA ZA2014/00644A patent/ZA201400644B/en unknown
-
2015
- 2015-04-01 IL IL238074A patent/IL238074A/en not_active IP Right Cessation
- 2015-06-02 US US14/728,826 patent/US9458228B2/en not_active Expired - Fee Related
- 2015-10-22 IL IL242207A patent/IL242207A0/en unknown
- 2015-12-28 US US14/981,643 patent/US9688745B2/en not_active Expired - Fee Related
-
2016
- 2016-01-07 JP JP2016001939A patent/JP2016135771A/ja active Pending
- 2016-08-24 US US15/246,301 patent/US9927428B2/en not_active Expired - Fee Related
- 2016-09-05 HK HK16110533.5A patent/HK1222418A1/zh unknown
- 2016-10-27 AU AU2016250398A patent/AU2016250398B2/en not_active Ceased
-
2018
- 2018-02-20 US US15/900,589 patent/US20180292391A1/en not_active Abandoned
- 2018-04-04 JP JP2018072444A patent/JP2018134089A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX350234B (es) | Compuestos de enlace especificos de bacterias gram-positivas. | |
PH12018501711A1 (en) | Compounds for treating spinal muscular atrophy | |
MX2014011134A (es) | Compuestos de carbamato y preparacion y uso de los mismos. | |
MX2011007930A (es) | Conjugados de insulina cristalina. | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
MX357834B (es) | Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. | |
MX2014010406A (es) | Compuestos para tratar atrofia muscular espinal. | |
MX358514B (es) | Compuestos para tratar la atrofia muscular espinal. | |
MY158992A (en) | Forms of rifaximin and uses thereof | |
MX343135B (es) | Compuestos de tipo fumagilol y métodos de realización y uso de los mismos. | |
MX2013004979A (es) | Inmunoglobulinas de dominio variable doble y usos de las mismas. | |
MX2013002270A (es) | Inmonoglubinas de dominio variable doble y usos de las mismas. | |
TW201206473A (en) | Dual variable domain immunoglobulins and uses thereof | |
MX355543B (es) | Macrociclos peptidomiméticos. | |
MX345762B (es) | Compuestos antiinfecciosos. | |
MX2009008347A (es) | Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso. | |
MX2009008430A (es) | Anticuerpos anti-robo4 y sus usos. | |
EP2273989A4 (en) | POLYTHERAPY FOR THE TREATMENT OF BACTERIAL INFECTIONS | |
MX2010008632A (es) | Leptina-polipeptidos modificados y sus usos. | |
MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
UA107204C2 (uk) | Протигрибкова композиція, що містить грибковий організм pythium oligandrum | |
PL2276498T3 (pl) | Zastosowanie bakterii probiotycznych do leczenia hiperhomocysteinemii | |
UA103468C2 (ru) | Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3 | |
EP2576575A4 (en) | PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF | |
MX2012000625A (es) | Compuestos de enlace especificos de bacterias gram-positivas. |